Clinical Trials Browser

Hematologic Neoplasms

Advanced Malignancies

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Renal Cell

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Endometrial Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Advanced Endometrial Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Squamous Cell Carcinoma of Head and Neck

Cholangiocarcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Recurrence

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Thyroid Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Clinical Trials

MK-3475-587

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

CLEAR

CheckMate 9DW

MK-6482-043

LEAP-003

LEAP-002

LEAP-006

LEAP-011

MK-7902-017

LEAP-001

LEAP-003

LEAP-012

MK-7902-014

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

LEAP-006

MK-3475-775

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

LEAP-007

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

CARE1

EMERALD-3

MK-6482-012

PREVENT-2

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

SELECT

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC